Samil PwC Report "Pharmaceutical Companies to Double Operating Profit by 2030 through AI Adoption"

Highest Impact of AI in Application and Operations
Cost Reduction and Performance Improvement from R&D to Commercialization
Additional $254 Billion Operating Profit Expected by 2030

As the adoption of generative artificial intelligence (AI) accelerates, global pharmaceutical companies are focusing on applying AI. In particular, pharmaceutical companies that have broadly implemented AI have secured the potential to double their operating profits by 2030. The impact of AI was greatest in operational areas such as production, raw materials, and supply chain costs.

On the 13th, Samil PwC published a report titled "Innovation in Pharmaceutical Companies Based on AI," which includes these findings. The report analyzed over 200 cases of AI application. It examined AI use cases in global pharmaceutical companies and proposed a three-step strategy for AI utilization.

According to the report, AI contributes to cost reduction and performance improvement in research and development (R&D), manufacturing and operations, go-to-market and commercialization, and support departments. The effect of AI application was highest in operations, accounting for 39% of profit potential. This was followed by R&D (26%), commercialization (24%), and support departments (11%) in terms of AI application efficiency.

The report forecasts that pharmaceutical companies actively adopting AI could gain an additional $254 billion in operating profits by 2030. It expects $155 billion in the United States, $52 billion in emerging markets, $33 billion in Europe, and $14 billion in other countries.

A three-step approach for pharmaceutical companies to realize AI potential was also presented. Step 1 involves internal organizational restructuring for AI adoption, Step 2 is forming dedicated teams for innovation, and Step 3 is the actual implementation of AI. Seoyongbeom, leader of the pharmaceutical and bio industry at Samil PwC, stated, "The level of AI adoption in domestic pharmaceutical companies is lower compared to global standards," adding, "Executive interest and government policy support are necessary."

Detailed information on the report can be found on the Samil PwC website.

This content was produced with the assistance of AI translation services.